How safe is a standard-risk child with ALL?

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 782-783

  Winther, Jeanette Falck ^a   Schmiegelow, Kjeld ^b,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILDHOOD CANCER; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; MAINTENANCE CHEMOTHERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; SECOND CANCER; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOPLASMS, SECOND PRIMARY; POPULATION SURVEILLANCE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84903514900     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70294-3     Document Type: Note

References (11)

1. Pui CH, Mullighan CG, Evans WE, Relling MV Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012, 120:1165-1174.
2. Farber S, Diamond LK Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948, 238:787-793.
3. Hudson MM, Neglia JP, Woods WG, et al. Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer 2012, 58:334-343.
4. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
5. D'Angio GJ Pediatric cancer in perspective: cure is not enough. Cancer 1975, 35(3 suppl):866-870.
6. Essig S, Li Q, Chen Y, et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2014, published online June 20. http://dx.doi.org/10.1016/S1470-2045(14)70265-7.
7. Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2013, 31:2469-2476.
8. Oeffinger KC, Sklar CA Childhood cancer, endocrine disorders, and cohort studies. Lancet 2014, 383:1950-1952.
9. Robison LL, Hudson MM Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 2014, 14:61-70.
10. Olsen JH, Moller T, Anderson H, et al. Lifelong cancer incidence in 47 697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009, 101:806-813.
11. de Fine LS, Winther JF, Gudmundsdottir T, et al. Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study. Lancet 2014, 383:1981-1989.